Thirty patients affected by previously untreated high risk myelodysplastic syndromes (MDS) were treated with human recombinant gamma-interferon (r-IFN-gamma): 15 of them with a higher dose (HD) of 0.1 mg/sqm, three times a week and 15 with a lower dose (LD) of 0.01 mg/sqm , three times a week, both doses administered subcutaneously (s.c.). The therapy was fairly well tolerated and few major toxic events were documented. Sustained improvement of one or more clinico-hematologic parameters was observed in 43.3% of the patients (26.6% and 60.0% for the lower and higher dose, respectively). Median survival time from the start of IFN-gamma therapy was 15+ months (range: 1-26) for patients with refractory anemia with excess of blasts (RAEB) versus 5 months (range 2-12) for patients with RAEB in transformation (RAEB-t); 15+ months (range 1-26) for HD patients versus 8 months (range 2-23) for patients treated with LD regimen; 16+ months (range 9-26) for responders versus 7 months (range 1-22) for nonresponders. All these three variables (diagnosis, treatment, and response to treatment) turned out to be statistically significant (p = at least < 0.01) at Cox's analysis.
RECOMBINANT GAMMA-INTERFERON AS 1ST LINE THERAPY FOR HIGH-RISK MYELODYSPLASTIC SYNDROMES / A. T., Maiolo; A., Cortelezzi; R., Calori; E. E., Polli; F., Gavosto; W., Piacibello; L., Resegotti; R., Paolino; E., Ascari; M., Cazzola; C., Bernasconi; E. P., Alessandrino; G. L., Castoldi; F., Mandelli; Alimena, Giuliana; ALOE SPIRITI, Maria Antonietta; B. M., Cesana. - In: LEUKEMIA. - ISSN 0887-6924. - 4(1990), pp. 480-485.